Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459472 | 0.73 | CA12 (0.31) | — | |
| SCHEMBL4989706 | 0.71 | TSHR (0.42) | ALDH1A1KDM4E | |
| SCHEMBL8725705 | 0.68 | LOX (0.36) | ALDH1A1KDM4ELOXAOC3HSD17B10 | |
| SCHEMBL248878 | 0.67 | CNR2 (0.46) | ALDH1A1LOXAOC3HSD17B10 | |
| SCHEMBL11006202 | 0.65 | ALDH1A1 (0.73) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30292271 | 0.64 | KDM4E (0.47) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL9935540 | 0.64 | TUBB1 (0.33) | ALDH1A1 | |
| SCHEMBL14200178 | 0.62 | KDM4E (0.49) | ALDH1A1KDM4E | |
| SCHEMBL2139323 | 0.62 | — | — | |
| SCHEMBL9592076 | 0.61 | SMN1; SMN2 (0.54) | ALDH1A1KDM4EAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2008-09-04 | — | — | US | disclosed |
| US-7375252-B2 | Compounds and method for the inhibition of the expression of VCAM-1 | ATHEROGENICS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7189870-B2 | Compounds and methods for the inhibition of the expression of VCAM-1 | ATHEROGENIC, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050090487-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | ATHEROGENICS, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | VCAM1, ICAM1, SELL | ALDH1A1 100/4885KDM4E 2945/4885LOX 242/4885 |
| US-20050090487-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | VCAM1, ICAM1, SELL | ALDH1A1 100/4885KDM4E 2945/4885LOX 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.